Caricamento...
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
BACKGROUND: Ovarian cancer is a leading cause of cancer-related mortality. Although the disease is relatively rare, it carries a disproportionately large morbidity burden. OBJECTIVE: We conducted a cost-utility analysis from a Canadian public payer perspective to determine the cost effectiveness of...
Salvato in:
| Pubblicato in: | Pharmacoecon Open |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer International Publishing
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5820234/ https://ncbi.nlm.nih.gov/pubmed/29464667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-017-0030-7 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|